Protagonist Therapeutics PE Ratio 2015-2022 | PTGX

Current and historical p/e ratio for Protagonist Therapeutics (PTGX) from 2015 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Protagonist Therapeutics PE ratio as of May 24, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Protagonist Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-25 7.86 0.00
2022-03-31 23.68 $-2.16 0.00
2021-12-31 34.20 $-2.70 0.00
2021-09-30 17.72 $-2.41 0.00
2021-06-30 44.88 $-1.92 0.00
2021-03-31 25.90 $-1.82 0.00
2020-12-31 20.16 $-2.00 0.00
2020-09-30 19.55 $-2.15 0.00
2020-06-30 17.66 $-2.55 0.00
2020-03-31 7.06 $-3.14 0.00
2019-12-31 7.05 $-3.00 0.00
2019-09-30 12.01 $-2.94 0.00
2019-06-30 12.11 $-2.71 0.00
2019-03-31 12.57 $-1.94 0.00
2018-12-31 6.73 $-1.72 0.00
2018-09-30 10.29 $-1.30 0.00
2018-06-30 6.72 $-1.21 0.00
2018-03-31 8.59 $-1.69 0.00
2017-12-31 20.80 $-2.17 0.00
2017-09-30 17.67 $-2.69 0.00
2017-06-30 11.31 $-3.27 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.375B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00